The ultimate goal is to discover new therapeutic opportunities beyond the currently available BRAF inhibitors, which are currently the only approved drugs, in combination with anti-EGFR therapies, for colorectal cancers with V600E mutations. The gene discussed is BRAF; the disease is colorectal cancer.